An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS

NCT07665437 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

710

Enrollment

INDUSTRY

Sponsor class

Conditions

Hidradenitis Suppurativa

Interventions

DRUG: Remibrutinib

Sponsor

Novartis Pharmaceuticals